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Abstract
Purpose Shoulder arthroplasties are increasingly per-
formed, but data on periprosthetic joint infections (PJI) in this
anatomical position are limited. We retrospectively investi-
gated the characteristics and outcome of shoulder PJI after
primary arthroplasty from 1998 to 2010 in a single centre.
Methods Periprosthetic joint infection was defined as
periprosthetic purulence, presence of sinus tract or micro-
bial growth. A Kaplan–Meier survival method was used to
estimate relapse-free survival of prosthesis.
Results From 1,571 primary shoulder prostheses, we
evaluated 16 patients with a PJI at different stages, i.e,
early (n = 4), delayed (n = 6) and late (n = 6) infections.
The median patient age was 67 (range 53–86) years, and
69 % were females. The most commonly isolated micro-
organism was Propionibacterium acnes in 38 % of patients
(monobacterial in four and polymicrobial in two patients).
In 14 of the 16 patients, surgical interventions consisting of
debridement and implant retention (6 patients), exchange
(7) and explantation (1) were performed. Four patients had
a relapse of infection with P. acnes (n = 3) or Bacteroides
fragilis (n = 1). The relapse-free survival of the prosthesis
was 75 % (95 % confidence interval 46–90 %) after 1 and
2 years, 100 % in six patients following the treatment
algorithm for hip and knee PJI and 60 % in 10 patients not
followed up. All but one of the relapses were previously
treated without exchange of the prosthesis.
Conclusions As recommended for hip and knee PJI, we
suggest treating shoulder PJI with a low-grade infection by
microorganisms such as P. acnes with an exchange of the
prosthesis. Cohort studies are needed to verify our results.
Keywords Shoulder arthroplasty  Prosthetic joint
infection  Surgical management  Treatment outcome 
Propionibacterium acnes
Introduction
Shoulder arthroplasties are becoming increasingly com-
mon, but data on shoulder periprosthetic joint infection
(PJI) are still limited. The incidence of prosthetic shoulder
infection varies from 0 to 1.9 % following primary
implantation [1–4]. In previous studies an underlying
trauma [2] or presence of a hematoma [5] were described
as risk factors for shoulder PJI. The most commonly
identified microorganisms in shoulder PJI are Staphylo-
coccus aureus, coagulase-negative staphylococci (CNS)
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and Propionibacterium acnes [2, 5]. Various surgical
procedures for treating PJI have been described in the lit-
erature, including a two-stage exchange [1, 6, 7], a one-
stage exchange [8], a resection arthroplasty [6, 7] or, as in
cases of acute infection, debridement and retention of the
prosthesis [1]. Antibiotic treatment or debridement alone
does not eradicate the infection [1]. Zimmerli et al. [9]
published an algorithm for hip and knee PJI in which they
suggest the most successful surgical approaches in combi-
nation with adequately chosen antibiotic treatment [9, 10].
The algorithm was developed on the basis of in vitro studies
and animal models of foreign body infections [9, 11–13]
and a limited number of clinical studies [14]. To date, no
information is available on the validity of this algorithm in
shoulder PJI. We therefore retrospectively evaluated all
patients from a 13-year cohort of primary shoulder arthro-
plasties at one orthopaedic centre in Switzerland.
Methods
Study population
The Schulthess Clinic is a specialised 160-bed orthopaedic
centre with a high rate of surgical interventions ([8,600
documented in 2011). We retrospectively reviewed all 1,
571 primary shoulder arthroplasties performed between
1998 and 2010 for PJI. Patients with a primary shoulder
prosthesis implantation in an extern hospital presenting
with a shoulder PJI at the Schulthess Clinic between 1998
and 2010 were also included in our study. Clinical infor-
mation on shoulder PJI was retrieved from the prospec-
tively managed database on all PJI from the Infectious
Diseases Clinical Consulting Service. Patients with an
incomplete documentation of PJI or follow-up were not
evaluated further.
Definitions
Shoulder PJI was diagnosed if one or more of the following
criteria were fulfilled: (1) visible purulence of a preopera-
tive aspirate or intraoperative periprosthetic tissue (as
determined by the surgeon), (2) presence of a sinus tract
communicating with the prosthesis, (3) microbial growth in
a preoperative joint aspirate, intraoperative periprosthetic
tissue or sonication fluid of the removed implant or (4)
synovial fluid with [1,700 leukocytes/ll or [65 % gran-
ulocytes, as determined in previous studies for knee PJI
[15]. For pathogens that are slow growing and promote an
indolent infection, such as CNS or Gram-positive anaer-
obes, the growth of the same organism in at least two
independent specimens was required. Postoperative infec-
tions were classified into early (within 3 months after
surgery), delayed (3–24 months) and late ([24 months
after surgery) infections based upon previous studies for
knee and hip implant infections [9, 16–18].
Microbiological diagnosis
Aspirated fluid and intraoperative periprosthetic tissue
specimens were cultured on blood agar plates, incubated
aerobically with 5 % CO2 and anaerobically at 35 C for
7 days (until July 2006) or 10 days (after July 2006) [19].
In addition, thioglycollate broth was inoculated and cul-
tured for 10 days. Isolated microorganisms were identified
and their antimicrobial susceptibility tested using standard
microbiological techniques [20]. After January 2007,
explanted shoulder prostheses were sonicated to improve
the detection of biofilm bacteria [21, 22].
Surgical treatment
The approach was individually determined at the surgeon’s
discretion. In the case of PJI, the type of revision was
chosen among three potential approaches: (1) debridement
and implant retention, (2) one-stage exchange or (3) two-
stage exchange of the implant.
Comparison with the treatment algorithm for hip
and knee PJI
We retrospectively determined whether the surgeon’s
decision was in agreement with the treatment algorithm for
hip and knee PJI [9, 16]. According to this algorithm the
least invasive surgical treatment should be used, while
retention of the implant is allowed only if all of the fol-
lowing four conditions are fulfilled: (1) short duration of
infection, including early postoperative infection (within
3 months after surgery) or acute hematogenous infection,
(2) short duration of clinical signs (not longer than
21 days), (3) surrounding soft tissue is not severely dam-
aged and (4) availability of antimicrobial agents active
against biofilms (e.g. rifampin for staphylococci and
quinolones for Gram-negative rods). If one or more of
these conditions were not fulfilled, retention of the implant
was considered inappropriate. In addition to surgical
treatment, we retrospectively determined whether the
antimicrobial therapy was in agreement with the recom-
mended treatment duration in hip and knee PJI, namely, at
least 3 months (maximum minus 15 days acceptable) for
debridement and retention and 4–6 weeks for a two-stage
exchange with a long interval [9, 16]. For the determination
of an adequate antibiotic treatment we did not take into
account the duration of the initial intravenous treatment
and the choice of antibiotics.
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Outcome evaluations
Follow-up in the orthopaedic outpatient clinic consisted of
regularly scheduled visits at 6 weeks, 3 months, 6 months,
1 year and 2 years after surgery. Only patients with at least
1 year of follow-up were evaluated in this study. Follow-up
examinations included clinical, radiological and laboratory
assessments. We defined a relapse of infection if signs of a
persistent infection (communicating sinus tract with the
prosthesis) were present and/or the same pathogen either as
monobacterial or polymicrobial infection was re-isolated.
A new infection was defined as a shoulder PJI at the same
anatomical site with isolation of a different microbial
pathogen.
Statistical analysis
GraphPad Prism 6 software (GraphPad, San Diego, CA)
was used for the statistical calculations and figures. The
probability of relapse-free survival of shoulder prosthesis
after 1 and 2 years and the 95 % confidence interval (95 %
CI) were estimated using Kaplan–Meier curves and the
log-rank test. Observations were censored at the time of
diagnosis of relapse of PJI.
Results
Between 1998 and 2010, 1,571 primary shoulder prosthe-
ses were implanted, i.e. a median number of 128 per year
(range 58–209). Nine (0.57 %) of the patients receiving the
prostheses suffered from PJI. In addition, seven patients
were referred for the treatment of their PJI. Characteristics
of all 16 patients are summarised in Table 1.
Microbiology
A microbiological diagnosis was performed preoperatively
and/or intraoperatively in 15 of 16 patients (94 %). In five
of the eight patients who had the implant removed (63 %),
cultures from the implant sonicate were performed in
addition to normal tissue cultures.
The most commonly isolated microbial species was
P. acnes, isolated as a monobacterial infection (4 cases,
25 %) and as polymicrobial infections (2 cases, 13 %).
Staphylococcus aureus (methicillin susceptible) was found
in two cases (13 %), and Escherichia coli, Bacteroides fra-
gilis, Peptostreptococcus magnus, Enterobacter aerogenes,
Corynbacterium bovis and Streptococcus dysgalactiae
subsp. equisimilis were found in one case each (6 %). The
one patient with negative intraoperative cultures at the time
of implant removal, based on seven tissue biopsies and
sonication fluid cultures being negative, was under antibiotic
treatment with amoxicillin–clavulanate for 14 days
(625 mg three times a day), thereby interfering with culture
results since P. acnes was found in two of six tissue cultures
at time of implantation of the new prosthesis. Susceptibility
testing of P. acnes by the E-test was performed on the isolates
from four of the six patients with positive P. acnes cultures
[20]. All strains were susceptible to amoxicillin [minimal
inhibitory concentration (MIC) 0.032–0.125 mg/l], clinda-
mycin (MIC 0.032–0.064 mg/l), ceftriaxone (MIC 0.25
mg/l), rifampin (MIC 0.002–0.004 mg/l and levofloxacin
(MIC 0.5 mg/l).
Treatment
Surgical procedures are summarised in Tables 1 and 2. In
seven patients with a two-stage prosthetic exchange, the
median time from explantation to implantation of the new
prosthesis was 3 (range 1.6–6.3) months. No surgical
treatment was performed in two patients with early infec-
tions either due to surgical preference or patient denial of
the revision. The median duration of the antibiotic treat-
ment was 92 (range 0–544) days, of which for 13 (median;
range 0–34) days the antibiotic was given intravenously. Of
Table 1 Characteristics of 16 episodes of shoulder periprosthetic
joint infection after primary shoulder arthroplasty with outcome
analysis
Characteristics No. of episodesa
Median age (years) 67 (53–86)
Female 11 (69)
Type of prosthesis
Anatomic 5 (31)
Inverse 11 (69)
Underlying joint disorder
Osteoarthritis 8 (50)
Trauma 6 (38)
Rheumatoid arthritis 2 (13)
Manifestation of PJI after last surgery
Early (\3 months) 4 (25)
Delayed (3–24 months) 6 (38)
Late ([24 months) 6 (38)
Surgical treatment
Debridement with implant retention 6 (38)
One-stage exchange 0 (0)
Two-stage exchange 7 (41)
Explantation of prosthesis 1 (6)
No surgery (antibiotics only) 2 (13)
PJI periprosthetic joint infection
a Data are presented as the number, with the percentage in paren-
thesis except for median age where the range is given in parenthesis.
Percentages are rounded off and may not add up to 100 %
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the ten patients with isolated staphylococci or P. acnes, five
received a combination treatment with rifampin.
Outcome evaluation
At last follow-up, 12 (75 %) patients were free of infection
(median follow-up time 2.7 years, range 2–8.7 years). Four
patients (25 %) had a relapse of infection (median 0.24
years, range 0.05–0.42 years), with an initial isolation of
P. acnes in two patients and Bacteroides fragilis and
negative cultures in one patient each. One patient died due
to non-infectious cause. One patient from whom Coryn-
bacterium bovis was isolated developed a new infection
with P. acnes after 2.6 years (n = 2). The relapse-free
survival rate of shoulder PJI was 75 % (95 % CI 46–90 %)
after 1 and 2 years (Fig. 1a). Table 2 summarises the
outcome of all 16 patients with respect to time to infection,
pathogenesis, isolated pathogen and the surgical procedure
that was performed. Relapse of infection occurred in one of
four cases of early infection (25 %), two of six cases of
delayed infection (33 %) and one of six cases of late
infection (17 %). Relapse of infection was also observed in
three of six patients (50 %) with debridement and implant
retention compared with two-stage exchange where one of
seven (17 %) patients developed a relapse of infection.
If the recommended treatment algorithm for hip and
knee PJI was followed (n = 6), the rate of relapse-free
survival of the prosthesis was 100 %. By contrast, if the
algorithm was not followed (n = 10), the relapse-free
survival was 60 % after 1 and 2 years (p \ 0.09) (Fig. 1b).
In terms of only surgical treatment, the relapse-free sur-
vival of the prosthesis was 87.5 % if the surgical procedure
was in line with the algorithm for hip and knee prosthesis
and 62.5 % if not (p \ 0.25).
Discussion
In our retrospective study we describe 16 patients with
shoulder PJI after primary implantation. The most com-
monly isolated microorganism was P. acnes. The predom-
inance of P. acnes in shoulder PJI is well known and might
be related to the anatomic location of the axillary lymph
glands [5, 9, 23–26]. P. acnes is an anaerobic Gram-positive
rod that needs a long culture period of 10–14 days [19]. It is
a major inhabitant of adult human skin, where it resides
within sebaceous follicles. We found this pathogen in four
cases as a monobacterial infection and in two cases as a
polymicrobial infection. In addition, one patient presented
with initial negative tissue cultures because of ongoing
antibiotic treatment with amoxicillin–clavulanate but later
demonstrated a positive culture for P. acnes. Therefore, we
consider that P. acnes was predominant in seven of the 16
patients (44 %) analysed in our study. This level is
remarkably different from what is commonly seen in cases
of hip and knee PJI, where staphylococci, streptococci and
Gram-negative bacteria are the major pathogens [16, 27].
Clinical trials and/or case reports provide little infor-
mation on the optimal antibiotic treatment for P. acnes in
PJI [23]. In our study, four of seven patients with P. acnes
infection received a combination of rifampin and either
amoxicillin or clindamycin. Recently published data from
an animal cage model showed the relevance of antibiotic
therapy with rifampin in combination with a potent second
drug to avoid rifampin resistance, with the highest cure rate
found with daptomycin and rifampin (63 %) [28]. Two
other antibiotics known to have significant efficacy against
P. acnes, amoxicillin and clindamycin, could not be tested
yearsPe
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Fig. 1 a Percentage of relapse-free survival of 16 shoulder Peripros-
thetic joint infections (PJI) after primary arthroplasty. Dotted lines
95 % confidence interval (CI). The relapse-free survival was 75 %
(95 % CI 46–90 %) after 1 and 2 years. b Percentage of relapse-free
survival of 16 shoulder PJI stratified according to if treated
accordingly (n = 6) or not (n = 10)
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in the guinea pig model because the animals do not tolerate
betalactams and clindamycin due to gastrointestinal tox-
icity. Further studies are needed to evaluate the optimal
treatment in humans. In one patient of our study with
relapse of P. acnes diagnosed at the time of implantation of
the new prosthesis, treatment was provided with oral
amoxicillin–clavulanate in the prosthesis-free interval,
which supports the importance of initial intravenous anti-
biotic therapy, which is recommended in most guidelines
[9, 29–31].
Despite the more invasive procedure, our results suggest
that exchange of the prosthesis should be the treatment of
choice in the majority of cases with shoulder PJI due to low-
grade infection. In three of our four patients (75 %) with
relapse of infection as evidence by the growth of P. acnes
and Bacteroides fragilis, only debridement and retention
without removal of the prosthesis was performed. Since
P. acnes and B. fragilis cause indolent and asymptomatic
infections for a prolonged period of time, a mature biofilm
is often definitively established at the time of diagnosis of
infection and exchange of foreign material is needed. This
result is in line with results of a retrospective study by
Sperling et al. [3], who reported a 50 % relapse of infection
if the shoulder prosthesis was not exchanged [3, 7].
According to the Kaplan–Meier analysis, the treatment
algorithm for hip and knee PJI can be adopted for a suc-
cessful outcome of shoulder PJI. We showed for the first
time in a small group of 16 shoulder PJI after primary
arthroplasty that the relapse-free survival of the prosthesis is
100 % if treated according to the published algorithm for
hip and knee PJI and 60 % after 2 years if not. The cure rate
in other studies following the algorithm was 94.3 % after
knee [17], 83 % [32] and 91 % [33] after hip and 100 %
after elbow arthroplasty [22].
Although this is a retrospective study using a prospective
database on PJI with a limited number of documented
shoulder PJI after primary shoulder arthroplasty, our study
is a systematic analysis of a large cohort in one single
centre. To date, there has been no evidence to facilitate the
choice of procedure in cases with shoulder PJI. Our findings
will allow surgeons and physicians active in the field of
infectious diseases to choose a more rational and possibly
more successful approach in the treatment of shoulder PJI.
In summary, the predominant microorganism in shoul-
der PJI and relapse of infection among our patients was
P. acnes. All but one of the relapses were previously
treated without exchange of the prosthesis. If the recom-
mended treatment algorithm for hip and knee PJI was
followed, the rate of relapse-free survival of the prosthesis
was 100 %. These data suggest that the treatment algorithm
developed for hip and knee PJI can be applied to shoulder
PJI. Further studies, particularly cohort studies, are needed
to verify our results.
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